Alpha Tau Medical’s (DRTS) Buy Rating Reaffirmed at HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 240.26% from the company’s previous close.

Alpha Tau Medical Stock Down 0.2 %

Shares of NASDAQ DRTS traded down $0.01 during trading hours on Monday, hitting $2.65. The company had a trading volume of 24,044 shares, compared to its average volume of 48,807. Alpha Tau Medical has a 1-year low of $1.75 and a 1-year high of $4.39. The firm’s 50 day moving average is $3.27 and its 200-day moving average is $2.79. The stock has a market capitalization of $184.95 million, a P/E ratio of -6.18 and a beta of 0.87.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). On average, sell-side analysts predict that Alpha Tau Medical will post -0.45 earnings per share for the current year.

Institutional Trading of Alpha Tau Medical

Several institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp boosted its stake in shares of Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock worth $151,000 after acquiring an additional 25,770 shares during the period. Renaissance Technologies LLC lifted its holdings in Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after purchasing an additional 26,800 shares during the last quarter. Finally, Levin Capital Strategies L.P. boosted its position in Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock worth $975,000 after purchasing an additional 7,189 shares during the period. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.